Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins.

Published

Journal Article (Review)

Progressive insulin secretory defects, due to either functional abnormalities of the pancreatic beta-cells or a reduction in beta-cell mass, are the cornerstone of type 2 diabetes. Incretin-based drugs hold the potential to improve glucose tolerance by immediate favorable effect on beta-cell physiology as well as by expanding or at least maintaining beta-cell mass, which may delay the progression of the disease. Long-term studies in humans are needed to elaborate on these effects.

Full Text

Duke Authors

Cited Authors

  • Salehi, M; Aulinger, BA; D'Alessio, DA

Published Date

  • May 2008

Published In

Volume / Issue

  • 29 / 3

Start / End Page

  • 367 - 379

PubMed ID

  • 18292465

Pubmed Central ID

  • 18292465

Electronic International Standard Serial Number (EISSN)

  • 1945-7189

International Standard Serial Number (ISSN)

  • 0163-769X

Digital Object Identifier (DOI)

  • 10.1210/er.2007-0031

Language

  • eng